Immuron Limited's (ASX:IMC) shares should open higher after obtaining approval to sell its Travelan diarrhea preventitive in Canada, through partner Paladin Labs Inc.
The authorization granted is for tablets comprising 200 milligrams of Immuron’s hyperimmune bovine colostrum.
In Canada, Travelan is classified as a natural health product and will be available to patients over the counter without prescription.
Paladin Labs will be able to claim on the product package that Travelan is "Clinically Proven to Help Reduce the Risk
of Travellers’ Diarrhea".
As Immuron continues to expand the Travelan global franchise, approval in Canada represents a significant milestone and is expected to be followed by additional licensing agreements and product approvals in other regions.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.